SGLT-2 inhibitors beyond diabetes: a new frontier in cancer treatment
- 27 September 2025
- journal article
- review article
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 229, 112925
Abstract
No abstract availableKeywords
This publication has 102 references indexed in Scilit:
- SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials balancing their risks and benefitsDiabetologia, 2022
- Canagliflozin Inhibits Glioblastoma Growth and Proliferation by Activating AMPKCellular and Molecular Neurobiology, 2022
- Repurposing sodium-glucose co-transporter 2 inhibitors (SGLT2i) for cancer treatment – A ReviewReviews in Endocrine and Metabolic Disorders, 2021
- SGLT2 and cancerPflügers Archiv - European Journal of Physiology, 2020
- Plasma metabolomic profile in prostatic intraepithelial neoplasia and prostate cancer and associations with the prostate-specific antigen and the Gleason scoreMetabolomics, 2020
- Helicobacter pylori infection leads to KLF4 inactivation in gastric cancer through a TET1‐mediated DNA methylation mechanismCancer Medicine, 2020
- Sodium–glucose cotransporter inhibitors and oxidative stress: An updateJournal of Cellular Physiology, 2018
- Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2Diabetologia, 2018
- Sodium–glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: Possible molecular pathwaysJournal of Cellular Physiology, 2018
- Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptakeInternational Journal of Cancer, 2017